Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Intranasal Anthrax Vaccine BW-1010
NCT04148118Phase 1Completed
- Sponsor
- BlueWillow Biologics
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BW-1010 in anthrax (7 arms), sponsored by BlueWillow Biologics. Primary endpoints: Frequency of solicited systemic and local reactions at Day 39, Frequency of Adverse Events (AE) at Day 85 and 2 more. Started Jan 2020; status: completed.
02
Drugs
BW-1010
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT04148118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148118.